AR and neoplasm: AR expression has been observed in various subtypes of OC and its activation has been linked to tumor growth and poor prognosis suggesting that targeting AR signaling, especially with AR antagonists such as enzalutamide, might represent a potential therapeutic strategy for OC [134–136].